Gestational diabetes mellitus (GDM) is a prevalent condition affecting approximately 7% of all pregnancies. As healthcare professionals, optimizing patient outcomes through comprehensive management is paramount. This article provides an overview of the best practices for managing this condition.
Early detection is crucial in managing GDM. The American Diabetes Association recommends universal screening for all pregnant women between 24 and 28 weeks of gestation using the glucose challenge test. A diagnosis is confirmed if the plasma glucose level one hour after a 50-gram glucose load is ≥140 mg/dL.
Dietary intervention is the cornerstone of GDM management. It involves meal planning to ensure appropriate weight gain, adequate nutrition, and euglycemia. A registered dietitian should provide individualized Medical Nutrition Therapy (MNT) to all GDM patients.
Regular physical activity complements MNT in managing GDM. It improves insulin sensitivity and aids in achieving euglycemia. Moderate-intensity exercise, such as brisk walking for at least 30 minutes daily, is recommended unless contraindicated.
If diet and exercise fail to achieve euglycemia, pharmacologic therapy is initiated. Insulin is the first-line treatment. However, oral hypoglycemic agents like metformin and glyburide are also considered safe and effective.
Postpartum care includes glucose testing 6-12 weeks after delivery to exclude type 2 diabetes, with lifelong screening for the development of diabetes or prediabetes. Lifestyle modifications should continue to prevent diabetes.
Optimizing outcomes in GDM involves a multidisciplinary approach encompassing screening, dietary intervention, physical activity, pharmacologic therapy, and vigilant postpartum care. As healthcare professionals, we play a pivotal role in managing this condition, thereby improving maternal and neonatal outcomes.
1.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
2.
Health researchers discuss Medicaid cancer screening trends, best practices
3.
Taking Charge of Your Cancer Journey.
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment
3.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
4.
A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation